TWI786132B - 活性抑制劑於發炎性疾病之治療 - Google Patents

活性抑制劑於發炎性疾病之治療 Download PDF

Info

Publication number
TWI786132B
TWI786132B TW107120362A TW107120362A TWI786132B TW I786132 B TWI786132 B TW I786132B TW 107120362 A TW107120362 A TW 107120362A TW 107120362 A TW107120362 A TW 107120362A TW I786132 B TWI786132 B TW I786132B
Authority
TW
Taiwan
Prior art keywords
antibody
amino acid
binding
human
ifx
Prior art date
Application number
TW107120362A
Other languages
English (en)
Chinese (zh)
Other versions
TW201904611A (zh
Inventor
郭仁峰
尼爾斯 萊德曼
Original Assignee
德商因夫萊亞斯有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 德商因夫萊亞斯有限公司 filed Critical 德商因夫萊亞斯有限公司
Publication of TW201904611A publication Critical patent/TW201904611A/zh
Application granted granted Critical
Publication of TWI786132B publication Critical patent/TWI786132B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
TW107120362A 2017-06-23 2018-06-13 活性抑制劑於發炎性疾病之治療 TWI786132B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
??17177657.8 2017-06-23
EP17177657 2017-06-23
EP17177657.8 2017-06-23
??17189938.8 2017-09-07
EP17189938 2017-09-07
EP17189938.8 2017-09-07

Publications (2)

Publication Number Publication Date
TW201904611A TW201904611A (zh) 2019-02-01
TWI786132B true TWI786132B (zh) 2022-12-11

Family

ID=62636193

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107120362A TWI786132B (zh) 2017-06-23 2018-06-13 活性抑制劑於發炎性疾病之治療

Country Status (10)

Country Link
EP (1) EP3642230A1 (ja)
JP (1) JP2020524696A (ja)
KR (1) KR20200020727A (ja)
CN (1) CN111201241A (ja)
AU (1) AU2018286754A1 (ja)
CA (1) CA3066689C (ja)
IL (1) IL271074A (ja)
SG (1) SG11201912882QA (ja)
TW (1) TWI786132B (ja)
WO (1) WO2018234118A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45235A (fr) 2016-06-14 2019-04-17 Regeneron Pharma Anticorps anti-c5 et leurs utilisations
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
CA3132771A1 (en) * 2019-03-14 2020-09-17 Morphosys Ag Antibodies targeting c5ar
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
US20230257454A1 (en) * 2020-06-24 2023-08-17 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing c5a and uses thereof
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
AU6501390A (en) 1989-09-21 1991-04-18 Synergen, Inc. Method for transporting compositions across the blood brain barrier
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
LT3385384T (lt) 2004-02-12 2020-09-25 Archemix Llc Aptamero terapija, naudinga su komplementu susijusių ligų gydymui
WO2005092366A1 (en) * 2004-03-26 2005-10-06 Promics Pty Limited TREATMENT OF NEUROLOGICAL CONDITIONS USING COMPLEMENT C5a RECEPTOR MODULATORS
WO2008009062A1 (en) 2006-07-21 2008-01-24 Promics Pty Ltd Treatment for intimal hyperplasia and related conditions
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
PL2381778T3 (pl) * 2008-12-22 2017-01-31 Chemocentryx, Inc. Antagoniści c5ar
GB0905790D0 (en) * 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
JP2013529647A (ja) * 2010-06-24 2013-07-22 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
ES2649490T3 (es) * 2013-03-14 2018-01-12 Alnylam Pharmaceuticals, Inc. Composiciones de ARNi contra el componente C5 del complemento y métodos para su uso
US20160060351A1 (en) * 2013-05-08 2016-03-03 Novo Nordisk A/S Use of C5AR Antagonists
WO2015140304A1 (en) * 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
EP3194596A1 (en) 2014-09-16 2017-07-26 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016061066A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
FR3030515B1 (fr) * 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
EP3313437A1 (en) 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
NZ747259A (en) 2016-04-04 2022-11-25 Chemocentryx Inc Soluble c5ar antagonists
IL261809B2 (en) * 2017-04-03 2024-04-01 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5A activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
期刊 Angela M. Finch,et al. "Low-Molecular-Weight Peptidic and Cyclic Antagonists of the Receptor for the Complement Factor C5a", J. Med. Chem. 1999, 42, 965-1974 *
期刊 E. Giamarellos-Bourboulis,et al. "Complement activation in hidradenitis suppurativa", Abstract - 2017 - Oral Presentation,Case O03-2, Experimental Dermatology , First published: 07 February 2017; *
期刊 Pirow Bekker et al, "Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study" , Plos One, 2016, Vol 11, pages 1-19.; *
網路文獻 inFlaRx, "InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anticomplementC5a antibody, in patients with Hidradenitis Suppurativa" 網址：https://uk.finance.yahoo.com/news/inflarxinitiatesexploratory- phase-ii-133001314.html, 2017年4月4日.; *

Also Published As

Publication number Publication date
IL271074A (en) 2020-01-30
TW201904611A (zh) 2019-02-01
AU2018286754A1 (en) 2019-12-19
EP3642230A1 (en) 2020-04-29
SG11201912882QA (en) 2020-01-30
JP2020524696A (ja) 2020-08-20
KR20200020727A (ko) 2020-02-26
CN111201241A (zh) 2020-05-26
CA3066689C (en) 2024-01-16
CA3066689A1 (en) 2018-12-27
WO2018234118A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
US11273225B2 (en) Treatment of inflammatory diseases with inhibitors of C5a activity
US11890349B2 (en) Treatment of inflammatory diseases with inhibitors of C5A activity
TWI786132B (zh) 活性抑制劑於發炎性疾病之治療
CN107638565B (zh) 用于治疗与masp-2依赖性补体活化相关的状况的方法
KR20150031298A (ko) 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
NZ719476A (en) Methods for treating conditions associated with masp-2 dependent complement activation
CN117398458A (zh) 用于治疗与masp-2依赖性补体活化相关的病况的方法
TW201920288A (zh) 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
KR20220159983A (ko) 코로나 바이러스 감염 치료를 위한 C5a의 억제제
AU2020201271A1 (en) Methods for treating conditions associated with MASP-2 dependent complement activation
EA043076B1 (ru) Лечение воспалительных заболеваний с помощью ингибиторов активности c5a
CA3159152A1 (en) Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplan
EA046178B1 (ru) Способы лечения и/или предотвращения реакции трансплантат против хозяина и/или диффузного альвеолярного кровотечения, и/или веноокклюзионной болезни, связанных с трансплантатом гемопоэтических стволовых клеток
EA042534B1 (ru) Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента